

**This Page Is Inserted by IFW Operations  
and is not a part of the Official Record**

## **BEST AVAILABLE IMAGES**

**Defective images within this document are accurate representations of the original documents submitted by the applicant.**

**Defects in the images may include (but are not limited to):**

- **BLACK BORDERS**
- **TEXT CUT OFF AT TOP, BOTTOM OR SIDES**
- **FADED TEXT**
- **ILLEGIBLE TEXT**
- **SKEWED/SLANTED IMAGES**
- **COLORED PHOTOS**
- **BLACK OR VERY BLACK AND WHITE DARK PHOTOS**
- **GRAY SCALE DOCUMENTS**

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**


 ERTY ORGANIZATION  
 ureau

A61L2/00P2F

R THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> :

A61L 2/08

A1

(11) International Publication Number:

WO 90/00907

(43) International Publication Date:

8 February 1990 (08.02.90)

(21) International Application Number: PCT/GB89/00839

(22) International Filing Date: 20 July 1989 (20.07.89)

(30) Priority data:  
8817240 20 July 1988 (20.07.88) GB(71) Applicant (for all designated States except US): SALFORD  
UNIVERSITY BUSINESS SERVICES LIMITED  
[GB/GB]; Business House, University Road, Salford M5  
4PP (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only) : MOORE, John, Stuart  
[GB/GB]; 19 Clifton Drive, Marple, Stockport, Cheshire  
SK6 6PP (GB). POWER, David, Moorfield [GB/GB];  
Roselle, Buxton Road, Chinley (GB). HASAN, Nail  
[PS/GB]; Department of Biological Sciences, University  
of Salford, Salford M5 4PP (GB).(74) Agent: ATKINSON, Peter, Birch; Marks & Clerk, Suite  
301, Sunlight House, Quay Street, Manchester M3 3JY  
(GB).(81) Designated States: AT (European patent), AU, BE (Euro-  
pean patent), CH (European patent), DE (European pa-  
tent), FR (European patent), GB (European patent), IT  
(European patent), LU (European patent), NL (Euro-  
pean patent), SE (European patent), US.

## Published

*With international search report.**Before the expiration of the time limit for amending the  
claims and to be republished in the event of the receipt of  
amendments.*

(54) Title: STERILISING METHODS

(57) Abstract

Methods for sterilising pharmaceutical formulations and gels which are exposed to high energy radiation to destroy micro-organisms are characterised in that a free radical scavenger is incorporated in the formulation or gel to scavenge those free radicals which would degrade the pharmaceutical or the gel. The free radical scavenger and its products are substantially non-reactive with the gel and are substantially non-toxic. Particularly suitable free radicals scavengers are mannitol and ribitol.


- 1 -

STERILISING METHODS


A first aspect of the present invention relates to a method for sterilising a pharmaceutical, in particular a pharmaceutical which is in aqueous solution.

The use of high energy radiations to destroy micro-organisms offers an alternative, and in some instances an attractive, means of sterilising pharmaceuticals compared with traditional techniques. In many instances it is cheaper, less energy consuming and provides better sterility assurance. Furthermore, it has none of the toxicity problems associated with gases (e.g. ethylene oxide) that are commonly used for sterilising purposes. However, radiation sterilisation of pharmaceuticals is often accompanied by chemical degradation, particularly in aqueous solutions, but also in other formulations such as gels, and this degradation must be minimised if the method is to be used successfully.

When dilute aqueous solutions are irradiated with high energy radiations (e.g.  $\gamma$  - or X-) the energy is completely absorbed by the water and produces highly reactive radicals ( $H^\cdot$ ,  $OH^\cdot$ ) and ions ( $e^-_{aq}$ ).



The reactions of these species are responsible for degradation of solute present. When oxygen is present,  $e^-_{aq}$  and  $H^\cdot$  are effectively removed:



- 3 -

- (iii) is non-toxic;
- (iv) yields toxic products;
- (v) does not cause protection to the bacteria (that are supposed to be killed).

Preferably the free radical scavenger is a polyhydric alcohol, for example mannitol or ribitol.

If the pharmaceutical formulation is an aqueous solution, the free radical scavenger is an additional solute in the aqueous solution and competes for the  $\text{OH}^\bullet$  radicals. Thus the free radical scavenger must react readily with  $\text{OH}^\bullet$  radicals, its own radiation degradation characteristics must be well known, it must be non-toxic, its products must be non-toxic and preferably easily metabolised, and for commercial reasons it should be inexpensive. These criteria are fully met in most circumstances by mannitol.

An embodiment of the first aspect of the present invention will now be described, by way of example.

Chloramphenicol is a pharmaceutical which is used in aqueous solution for eye-drops. Mannitol which is a polyhydroxyalcohol was introduced as a solute into aqueous solutions of chloramphenicol (hereinafter CP) and the resultant aqueous solutions were exposed to radiation at a variety of mannitol and CP concentrations. The mannitol reacts with  $\text{OH}^\bullet$  radicals with a diffusion-controlled rate constant to yield almost entirely mannose and fructose (as assayed using GC and HPLC). The results are given in table 1 below.

- 5 -

Table 2

$\gamma$  -irradiation of preoxygenated CP (0.5% w/v) with different polyhydric alcohols in borate buffer (1.5%), pH 7. Total dose received 25kGy. Dose rate 540Gy min<sup>-1</sup>

polyhydric alcohols (mol <sup>-3</sup> dm <sup>-3</sup> )	1 Remaining postirradiation				products formed				3 calculated degradation of polyalcohols	
	HPLC Sample	CP	GC Sample	CP	pH	Colour	mol <sup>-3</sup> dm <sup>-3</sup>			
-	-	50	-	60	7	intense yellow	-		-	
Mannitol 0.27	100	97	100	98.5	7	almost colourless	Mannose 0.3x10 <sup>-2</sup>	Fructose 0.2x10 <sup>-2</sup>	3 or 4 Carbon compound	1.85
Sorbitol 0.3	99	89	100	108	7		"	Glucose 0.33x10 <sup>-2</sup>	Fructose 0.1 x10 <sup>-2</sup>	Arabinose 3,4 Carbon
Galactitol 0.37	99	85	100	88	7	"	Galactose 0.75x10 <sup>-2</sup>	Tagatose 0.09x10 <sup>-2</sup>	3,4 carbon compound	3
Erythritol 0.41	99	94	98.8	92	7	"	Erythrose 0.45x10 <sup>-2</sup>	-	-	1.1
Arabinitol 0.3	97.5	87	106	83	7	"	Arabinose 0.3 x10 <sup>-2</sup>	-	3,4 carbon compound	1.0
Ribitol 0.33	107	83	98.5	94	7	"				
Glycerol 0.28	98.2	88	100	98	7	"				

The irradiation of the CP in the absence of a radical scavenger produces an intense yellow coloured solution indicating that substantial degradation had occurred. In the presence of a radical scavenger almost colourless solutions of the CP were obtained after irradiation thus indicating that no substantial degradation had occurred.

It can be seen from the results set out above that mannitol is particularly effective in protecting CP against degradation but other polyhydric alcohols also produce good results.

A second aspect of the invention relates to the sterilisation of alginate gels. Such gels cannot currently be sterilised by irradiation or by heating.

For example, gels prepared from 1%, 2% and 3%

- 7 -

The same gel without mannitol is also fully flexible. After irradiation (25KGy) the mannitol containing gel can still be bent through an angle of 80°. In marked contrast the gel irradiated without mannitol breaks when bent through an angle of 10°. Such a gel is not usable.

When a 2% alginate gel containing 18% mannitol is prepared with an open nylon mesh incorporated into it. The gel, even after a dose of 25KGy can be bent through 180° (i.e. is fully flexible) and moreover is easily manipulated.

- 9 -

scavenger is incorporated in the gel to scavenge those free radicals which could degrade the gel, the said free radical scavenger and its products being non-reactive with the gel and being substantially non-toxic.

11. A method as claimed in Claim 10 wherein the gel is an alginate gel.

12. A method as claimed in Claim 10 and 11 wherein the free radical scavenger is a polyhydric alcohol.

13. A method as claimed in Claim 12 wherein the polyhydric alcohol is mannitol or ribitol.

14. A method as claimed in any one of Claims 10 to 13 wherein the gel is an alginate gel.

15. A method as claimed in any one of Claims 10 to 14 wherein the gel to be sterilised comprises up to 25% of the free radical scavenger.

16. A method for sterilising a gel substantially as hereinbefore described.

# INTERNATIONAL SEARCH REPORT

International Application No PCT/GB 89/00839

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC IPC <sup>5</sup> : A 61 L 2/08		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
IPC <sup>5</sup> :	A 61 L	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup></b>		
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with Indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
X	Microbiology Abstracts, section A, vol. 9, no. 10, October 1973 Information Retrieval Ltd. (London, GB) H. Affolter et al.: "The antimicrobial treatment of medicaments by gamma-rays" see page 94, abstract 9A6126 & Pharm. Acta Helvetica, 48(10), 525-40, 1973	1,3
--		
X	Chemical Abstracts, vol. 73, no. 13, 28 September 1970, (Columbus, Ohio, US), G. Hangay et al.: "Radiosterilization of an ophtalmic ointment containing hydrocortisone and chloramphenicol" II. Ointment base constituents" see page 226, abstract 69804g & Acta Pharm. Hung. 1970, 40(2), 75-80 -----	1,3,5,9
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p><sup>10</sup> Special categories of cited documents: <sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
23rd November 1989	18. 12. 89	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	<div style="border-bottom: 1px solid black; display: inline-block; width: 150px;"></div> T.K. WILLIS	